Science News for Scientific Sessions 2019

John J V McMurray | BHF Cardiovascular Research Centre, Glasgow, United Kingdom

Results: In HFrEF patients both with and without T2DM, dapagliflozin + standard therapy reduced the risk of worsening HF events and CV death and improved symptoms.

See our special in-depth DAPA-HF page for slides, videos and commentary from this study.

R. Scott Wright | Mayo Clinic, Rochester, MN

Results: Twice-yearly inclisiran safely reduced LDL-C in ASCVD patients with continued high LDL-C while on maximum tolerated statin dose.

See our special in-depth ORION-10 page for slides, videos and commentary of this study.

Jean-Claude Tardif | Montreal Heart Institute, Montreal, QC, Canada

Results: Colchicine compared to placebo reduced the risk of ischemic CV events in patients with a recent MI.

See our special in-depth COLCOT page for slides, videos and commentary of this study.

Kausik K Ray, Imperial College of London, London, United Kingdom

Results: In patients with ACS, DM, and low HDL-C, apabetalone, a selective BET protein inhibitor, did not significantly improve CV outcomes. CV outcomes trend was favorable.

See our special in-depth BETonMACE page for slides, videos and commentary of this study.

Judith S Hochman | NYU School of Medicine, New York, NY; ISCHEMIA Research Group

Results: In SIHD patients with moderate-severe ischemia, initial revascularization + OMT compared to OMT alone did not reduce the risk for adverse CV outcomes.

See our special in-depth ISCHEMIA page for slides, videos and commentary of this study.

Sripal Bangalore| New York University School of Medicine, New York, NY; ISCHEMIA-CKD Research Group

Results: In SIHD patients with moderate-severe ischemia and CKD, the risk of adverse clinical outcomes with an initial invasive strategy was not reduced compared to an initial conservative OMT strategy.

See our special in-depth ISCHEMIA-CKD page for slides, videos and commentary of this study.

George Dangas | Mount Sinai Hospital, New York, NY

Results: More complications were seen with rivaroxaban-based vs antiplatelet-based antithrombotic therapy after TAVR in patients without an established indication for anticoagulation. Study suggests routine anticoagulation with rivaroxaban after TAVR not needed in the absence of another specific indication. Future trials needed.

See our special in-depth GALILEO page for slides, videos and commentary of this study.

Ole De Backer | Rigshospitalet University Hospital, Copenhagen, Denmark

Results: CT imaging finds decrease in subclinical leaflet thrombosis in TAVR valves with rivaroxaban-based strategy compared to antiplatelet-based strategy. Perspective needed in light of GALILEO findings.

De Backer's Abstract
De Backer's Presentation Slides (PDF)
Discussant Slides (PDF) for GALILEO-4D
Published in NEJM: Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Eric Van Belle | Institute Coeur Poumon - CHU Lille, Lille, France

Results: Registry comparison identifies need for trial to compare latest generation of self- and balloon-expandable valves for para valvular regurgitation and mortality after TAVR.

Van Belle's Abstract
Van Belle's Presentation Slides (PDF)
Discussant Slides (PDF) for Van Belle
Published in Circulation: Balloon-Expandable versus Self-Expanding Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison from The France-TAVI Registr

Duk-Hyun Kang | Asan Medical Center, Seoul, Republic of Korea

Results: Composite and all-cause death were lower with early surgery versus conventional treatment for asymptomatic, severe AS.

See our special in-depth RECOVERY page for slides, stats and background of this study.

Usman Baber | Icahn School of Medicine at Mount Sinai, New York, NY

Results: Subgroup analysis of ticagrelor alone versus ticagrelor + aspirin in NSTE-ACS after PCI found less clinically relevant bleeding; similar rates of death, MI, and stroke.

Baber's Abstract
Baber's Presentation Slides (PDF)
Discussant Slides (PDF) for Baber

Binita Shah | VA NY Harbor Healthcare System, NYU School of Medicine, New York, NY

Results: Pre-PCI colchicine reduced post PCI inflammation but not the risk of PCI-related myocardial injury.

See our special in-depth Colchicine-PCI page for slides, videos and commentary of this study

Natalia Pinilla Echeverri | McMaster University, Hamilton, ON, Canada

Results: Obstructive non-culprit lesions with complex vulnerable plaque morphology found in almost half of STEMI and multi-vessel disease patients.

Echeverri's Abstract
Echeverri's Presentation Slides (PDF)
Discussant Slides (PDF) for Echeverri

Jorrit Lemkes | Amsterdam University Medical Center, Amsterdam, Netherlands

Results: Outcomes at 1 year for immediate coronary angiography after non-STEMI cardiac arrest were not better than a delayed strategy.

Lemkes's Abstract
Lemkes's Presentation Slides (PDF)
Discussant Slides (PDF) for Lemkes

Sanket Dhruva | UCSF School of Medicine, San Francisco, CA

Results: Observational analysis of cardiogenic shock and high-risk PCI patients found the Impella® ventricular assist device was associated with more death, bleeding, stroke and higher costs than intra-aortic balloon pumps.

Dhruva's Abstract
Dhruva's Presentation Slides (PDF)
Discussant Slides (PDF) for Dhruva

Amit P Amin | Washington University School of Medicine, Saint Louis, MO

Results: Released after presentation

Amin's Abstract
Amin's Presentation Slides (PDF)
Discussant Slides (PDF) for Amin
Published in Circulation: The Evolving Landscape of Impella™ Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention with Mechanical Circulatory Support

David J Goldberg, Children's Hospital of Philadelphia, Philadelphia, PA

Results: Exercise performance measures, but not oxygen consumption at peak exercise, improved with udenafil treatment after Fontan. More study needed.

Goldberg's Abstract
Goldberg's Presentation Slides (PDF)
Discussant Slides (PDF) for Goldberg
Published in Circulation: Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial

Felipe Martinez |Insto Damic, Cordoba, Argentina

Results: Dapagliflozin + standard therapy reduced the risk of worsening HF events and CV death, and improved symptoms across age groups for patients with HFrEF.

Martinez's Abstract
Martinez's Presentation Slides (PDF)
Discussant Slides (PDF) for Martinez
Published in Circulation: Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Mikhail Kosiborod | St. Luke's Health System, Kansas City, MO

Results: HFrEF patients reported improved symptoms, function, and HF-QOL with dapagliflozin compared to placebo across the range of health status outcomes.

McMurray's KCCQ Abstract
McMurray's KCCQ Presentation Slides (PDF)
Discussant Slides (PDF) for McMurray's KCCQ
Published in Circulation: Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

John J McMurray | University of Glasgow, Glasgow, United Kingdom

Results: A comparison of the therapeutic effects of sacubitril/valsartan, compared to enalapril or valsartan alone across the spectrum of EF in HF showed therapeutic benefits vary by LVEF. Primary composite event rates decreased as LVEF increased.

McMurray's PARAGON-HF Abstract
McMurray's PARAGON-HF Presentation Slides (PDF)
Discussant Slides (PDF) for McMurray's PARAGON-HF
Published in Circulation: Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF

Scott D Solomon, Brigham and Women's Hospital, Boston, MA

Results: A comparison of the effects of sacubitril/valsartan, compared to renin angiotensin system inhibition across the spectrum of EF in HF showed composite primary events decreased as LVEF increased.

Solomon's Abstract
Solomon's Presentation Slides (PDF)
Discussant Slides (PDF) for Solomon
Published in Circulation: Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Matthew J Budoff | Lundquist Institute and UCLA School of Medicine, Torrance, CA

Results: Icosapent ethyl added to statin therapy in patients with elevated triglycerides significantly slowed coronary atherosclerosis progression.

Budoff's Abstract
Budoff's Presentation Slides (PDF)
Discussant Slides (PDF) for Budoff

Frederick J Raal | Johannesburg Hospital, Johannesburg, South Africa

Results: In patients with heterozygous familial hypercholesterolemia and on maximally tolerated statin dose, twice-yearly inclisiran safely reduced LDL-C approximately 50%.

See our special in-depth ORION-9 page for slides, videos and commentary of this study

Christie M Ballantyne | Baylor College of Medicine, Houston, TX

Results: In healthy patients and those with severe hypertriglyceridemia and familial chylomicronemia syndrome, ARO-APOC3, a RNAi-based therapy, successfully reduced hepatocyte expression of APOC3, a component of triglyceride-rich lipoproteins, and plasma triglycerides.

Ballantyne's Abstract
Ballantyne's Presentation Slides (PDF)
Discussant Slides (PDF) for Ballantyne

Gerald F Watts | University of Western Australia, Royal Perth Hospital, Perth, Australia

Results: In this phase 1 study for patients with dyslipidemia, targeting ANGPTL3 with the RNAi drug, ARO-ANG3, resulted in a reduction in ANGPTL3 and mean triglyceride and LDL-C.

Watts's Abstract
Watts's Presentation Slides (PDF)
Discussant Slides (PDF) for Watts

Pierre Amarenco | Paris University, Paris, France

Results: Following an atherosclerotic ischemic stroke, reducing LDL-C to <70 mg/dL compared to 100±10 mg/dL resulted in lower risk for more CV events.

See our special in-depth Treat Stroke to Target page for slides, videos and commentary of this study